Metraipolis › archive › dc_4d72c602e2b2
Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area — Europe PMC PMID:34507347
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34507347
- DOI
- 10.1371/journal.pone.0257182
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-02T21:13:47.719Z
- SHA-256 of the archived text
184e67178a87d349e27abf36d9eb4a127ebe01c48db8855d426f599d408257dc- Stable URL of this page
https://metraipolis.com/documento/dc_4d72c602e2b2
How to cite
Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area — Europe PMC PMID:34507347 — Europe PMC (en), https://europepmc.org/article/MED/34507347 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_4d72c602e2b2 (Metraipolis archive dc_4d72c602e2b2, sha256 184e67178a87d349e27abf36d9eb4a127ebe01c48db8855d426f599d408257dc)
BibTeX
@misc{dc4d72c602e2b2,
title = {Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area — Europe PMC PMID:34507347},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34507347},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_4d72c602e2b2; sha256 184e67178a87d349e27abf36d9eb4a127ebe01c48db8855d426f599d408257dc},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34507347. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: The dengue vaccine (Dengvaxia) is only recommended for individuals with prior dengue infection (PDI). This study aimed to perform a serosurvey to inform decision-making for vaccine introduction and identify appropriate target populations. We also evaluated the performance of the serological tests using plaque reduction neutralization test (PRNT) as a reference test in identifying PDI to determine suitability for pre-vaccination screening. Methods: We enrolled 115 healthy individuals between 10 and 22 years of age living in the Ratchaburi province of Thailand. The serum samples were tested by PRNT to measure the prevalence and concentration of serotype-specific neutralizing antibodies. The performance of the IgG rapid diagnostic test (RDT, SD Bioline, Korea) and IgG enzyme-linked immunosorbent assay (ELISA, EUROIMMUN, Germany) in identifying PDI were evaluated by using PRNT as a reference method. Results: Ninety-four (81.7%) individuals neutralized one or more dengue serotypes at a titer threshold greater than or equal to 10. Multitypic profiles were observed in 70.4% of the samples which increased to 91.9% in subjects aged 19-22. Among monotypic samples, the highest proportion was reactive against DENV-1 followed by DENV-2, DENV-3, and DENV-4. The highest anti-dengue antibody titers were recorded against DENV-1 and increased with age to a geometric mean NT50 titer (GMT) of 188.6 in the 19-22 age group. While both RDT and ELISA exhibited 100% specificity, RDT demonstrated low sensitivity (35%) with ELISA displaying much greater sensitivity (87%). Conclusions: Almost 80% of adolescents and youth in Ratchaburi province had already been exposed to one or more of the dengue virus serotypes. The dengue IgG RDT displayed low sensitivity and is likely not be suitable for dengue pre-vaccination screening. These results support the use of IgG ELISA test for dengue vaccination in endemic areas. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-09-10). Identificativi: PMID 34507347 · PMCID PMC8432984 · DOI 10.1371/journal.pone.0257182. Descrittori MeSH principali: Mass Screening; Vaccination; Endemic Diseases. Pagina: https://europepmc.org/article/MED/34507347 — https://doi.org/10.1371/journal.pone.0257182. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-02T21:06:49.435Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.